Is the multidisciplinary team essential for the future management of patients with inflammatory bowel disease?

Colorectal Disease

Volumn 9, Issue 6, 2007, Pages 478-479

  Windsor, A ^a   Forbes, A ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESS TO INFORMATION; CANCER SURVIVAL; CLINICAL PRACTICE; CONSULTATION; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DELAYED DIAGNOSIS; EDITORIAL; EDUCATION PROGRAM; ENTERITIS; HEALTH CARE ACCESS; HEALTH CARE COST; HUMAN; INTERDISCIPLINARY COMMUNICATION; INTERDISCIPLINARY EDUCATION; INTESTINE SURGERY; MEDICAL AUDIT; MEDICAL SPECIALIST; MORBIDITY; MORTALITY; PATIENT REFERRAL; PATIENT SATISFACTION; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; RECTUM CANCER; TEAMWORK; ULCERATIVE COLITIS; UNITED KINGDOM;

GASTROENTEROLOGY; HUMANS; INFLAMMATORY BOWEL DISEASES; MEDICAL ONCOLOGY; PATIENT CARE TEAM;

EID: 34250705195     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2007.01293.x     Document Type: Editorial

References (15)

1. Expert Advisory Group on Cancer. (1995) A Policy Framework for Commissioning Cancer Services: A Report to the Chief Medical Officer of England and Wales. The Claman-Hine Report. Department of Health, London.
2. Haward RA. The Calman-Hine report: A personal retrospective on the UK's first comprehensive policy on cancer services. Lancet Oncol 2006; 7: 336-46.
3. Junor EJ, Hole DJ, Gillis CR. Management of ovarian cancer: Referral to a MDT matters. Br J Cancer 1994; 70: 363-70
4. Stephens MR, Lewis WG, Brewster AE et al. MDT management is associated with improved outcomes after surgery for oesophageal cancer. Dis Oesophagus 2006; 19: 164-71.
5. Burton S, Brown G, Daniels IR et al. MRI directed MDT preoperative treatment strategy: The way to eliminate positive cirumferential margins? Br J Cancer 2006; 94: 351-7.
6. Jessop J, Beagley C, Heald RJ. The Pelican Cancer Foundation and The English MDT-TME Development Programme. Colorectal Dis 2006; 8(Suppl. 3): 1-2.
7. Moum B, Ekbom A, Vatn MH, Aadland E, Sauar J, Lygren I, Schulz T, Stray N, Fausa O. Inflammatory bowel disease: Re-evaluation of the diagnosis in a prospective population based study in south eastern Norway. Gut 1997; 40: 328-32.
8. Canavan C, Abrams KR, Hawthorne B, Drossman D, Mayberry JF. Long-term prognosis in Crohn's disease: Factors that affect quality of life. Aliment Pharmacol Ther 2006; 23(3): 377-85.
9. Myrelid P, Andersson P, Sjödahl R, Olaison G. Immunosuppression for Crohn's disease is associated with increased frequency of anastomotic complications. Colorectal Dis 2004; 6: 26.
10. Su C, Lichtenstein GR, Krok K, Brensinger CM, Lewis JD. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 2004; 126: 1257-69.
11. Etienney I, Bouhnik Y, Gendre JP et al. Crohn's disease over 20 years after diagnosis in a referral population. Gastroenterol Clin Biol 2004; 28: 1233-9.
12. Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, Williams CB, Price AB, Talbot IC, Forbes A. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006; 130: 1030-8.
13. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980; i: 514-514.
14. Walmsley RS, Ayres RCS, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998; 443: 29-32.
15. Johnson JA, Coons SJ. Comparison of the EQ-5D (EuroQol) and SF-12 in an adult US sample. Qual Life Res 1998; 7: 155-66.